[go: up one dir, main page]

MX2016009991A - Nuevo anticuerpo anti-dengue de espectro completo. - Google Patents

Nuevo anticuerpo anti-dengue de espectro completo.

Info

Publication number
MX2016009991A
MX2016009991A MX2016009991A MX2016009991A MX2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A
Authority
MX
Mexico
Prior art keywords
dengue
antibody agents
full spectrum
new anti
spectrum antibody
Prior art date
Application number
MX2016009991A
Other languages
English (en)
Other versions
MX375402B (es
Inventor
Sasisekharan Ram
Tharakaraman Kannan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2016009991A publication Critical patent/MX2016009991A/es
Publication of MX375402B publication Critical patent/MX375402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona, entre otras cosas, agentes anticuerpos (por ejemplo, anticuerpos, y/o sus fragmentos de unión a antígeno) que se unen a epítopos del DV, así como composiciones que los contienen y método para diseñar, proporcionar, formular, usar, identificar y/o caracterizarlos. En algunas modalidades, los agentes anticuerpos provistos muestran una unión significativa a una pluralidad de serotipos del DV. En algunas modalidades, los agentes anticuerpos provistos muestran una unión significativa a los cuatro serotipos del DV. Tales agentes anticuerpos son útiles, por ejemplo, en la profilaxis, tratamiento, diagnóstico, y/o estudio del DV.
MX2016009991A 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo. MX375402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (2)

Publication Number Publication Date
MX2016009991A true MX2016009991A (es) 2016-10-07
MX375402B MX375402B (es) 2025-03-06

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009991A MX375402B (es) 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo.

Country Status (12)

Country Link
US (3) US9902764B2 (es)
EP (1) EP3104888A4 (es)
JP (1) JP6707455B2 (es)
KR (1) KR20160119806A (es)
CN (1) CN106413749B (es)
AU (1) AU2015217149B2 (es)
BR (1) BR112016017764A2 (es)
CA (1) CA2938495A1 (es)
IL (1) IL246788A0 (es)
MX (1) MX375402B (es)
SG (2) SG10201807826XA (es)
WO (1) WO2015123362A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP2882453B1 (en) 2012-08-07 2021-01-06 Massachusetts Institute of Technology Anti-dengue virus antibodies and uses thereof
AU2015217572B2 (en) * 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof
SG10201807826XA (en) 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
AU2017238651B2 (en) 2016-03-25 2024-06-13 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
KR102595080B1 (ko) 2016-12-23 2023-10-30 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 포유류 세포 배양에서 항체 생산성을 증강시키고 하류 제제화 프로세스 동안 응집을 최소화하기 위한 개선된 방법, 및 그로부터 수득된 안정한 항체 제제
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
SI1556477T1 (sl) 2002-11-01 2017-12-29 Glaxosmithkline Biologicals S.A. Sušilni postopek
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
EP2257624B9 (en) 2008-02-05 2012-08-01 Medical Research Council Methods and compositions
EA201170353A1 (ru) 2008-10-05 2011-12-30 Зэ Борд Оф Трастис Оф Зэ Лилэнд Стэнфорд Джуниор Юниверсити Антитела против гепатита с и их применение
CN108610416B (zh) 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CN102573905A (zh) 2008-12-05 2012-07-11 勒帕斯公司 利用抗脂类抗体晶体结构的抗体设计
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
EP2882453B1 (en) 2012-08-07 2021-01-06 Massachusetts Institute of Technology Anti-dengue virus antibodies and uses thereof
SG10201807826XA (en) * 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
AU2015217572B2 (en) * 2014-02-11 2020-10-15 Visterra, Inc. Antibody moleules to dengue virus and uses thereof

Also Published As

Publication number Publication date
AU2015217149B2 (en) 2020-09-10
MX375402B (es) 2025-03-06
EP3104888A1 (en) 2016-12-21
US10519220B2 (en) 2019-12-31
CA2938495A1 (en) 2015-08-20
KR20160119806A (ko) 2016-10-14
US11421018B2 (en) 2022-08-23
US9902764B2 (en) 2018-02-27
JP2017507131A (ja) 2017-03-16
US20200207841A1 (en) 2020-07-02
WO2015123362A1 (en) 2015-08-20
US20180237504A1 (en) 2018-08-23
IL246788A0 (en) 2016-08-31
US20150368321A1 (en) 2015-12-24
CN106413749B (zh) 2022-04-05
SG10201807826XA (en) 2018-10-30
CN106413749A (zh) 2017-02-15
AU2015217149A1 (en) 2016-09-08
JP6707455B2 (ja) 2020-06-10
EP3104888A4 (en) 2017-08-09
SG11201606163QA (en) 2016-08-30
BR112016017764A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MX2016009991A (es) Nuevo anticuerpo anti-dengue de espectro completo.
MX2016015398A (es) Moleculas de union tri-especificas y metodos de uso de las mismas.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
MX2017001597A (es) Anticuerpos anti-pd-l1.
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
MX2017007744A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
CR20170079A (es) Agentes de unión a cd123 y usos de estos
MX2018002043A (es) ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
CO2017000016A2 (es) Diacuerpos heterodiméricos biespecíficos capaces de unirse en forma específica a un epítopo de p-cadherina y a un epítopo de cd3 que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica y composiciones farmacéuticas de los mismos
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
AR100679A1 (es) Anticuerpos tri-específicos
MX2017013723A (es) Anticuerpo igf-ir y su uso para el diagnostico del cancer.

Legal Events

Date Code Title Description
FG Grant or registration